Last reviewed · How we verify
NCT05132205
Radiofrequency Ablation of Papillary Thyroid Microcarcinoma
NA trial testing Radiofrequency Ablation in Papillary Thyroid Cancer in 10 participants. Completed in 19 November 2024.
19 November 2024
Quick facts
| Lead sponsor | Johns Hopkins University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 17 December 2021 |
| Primary completion | 19 November 2024 |
| Estimated completion | 19 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Radiofrequency Ablation
Conditions studied
- Papillary Thyroid Cancer — all drugs for Papillary Thyroid Cancer →
Sponsor
Johns Hopkins University
Who can join
Adults 18 to 100, any sex, with Papillary Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Traditionally, surgery has been the standard recommendation for treating papillary thyroid cancer. The risk of surgery including permanent hoarseness, permanent hypocalcemia, a mid-cervical scar, and the potential for permanent hypothyroidism may be unacceptable for some patients, especially with low risk papillary thyroid carcinoma. The recent American Thyroid Association guidelines have proposed the option of active surveillance with low risk papillary thyroid cancer less than 210 mm. However, most patients find observation anxiety provoking knowing of having cancer. Radiofrequency ablation (RFA) of small low risk papillary thyroid cancer is a promising therapeutic modality for these patients that reduces the risks associated with surgery and the anxiety of taking a watchful approach. However, this technique has not been validated in the North American population. The investigators aim to describe the investigators' initial experience with RFA of low risk papillary thyroid microcarcinoma (PTMC) compared to active surveillance (AS) done by Head and Neck Endocrine surgeons at Johns Hopkins Medical Institute. Primary objective: * To evaluate the safety, efficacy and oncological outcomes of the procedure. Secondary objective: * To determine the patient functional outcomes in comparison to the observational control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05132205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiofrequency Ablation
Trials testing the same drug.
- NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting
- NCT06791629 — Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation · NA · not yet recruiting
- NCT05473663 — Radiofrequency Ablation After Total Knee Arthroplasty · NA · active not recruiting
- NCT05003856 — Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule · NA · terminated
- NCT05433701 — Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC · NA · active not recruiting
Other recruiting trials for Papillary Thyroid Cancer
Currently open trials in the same condition.
- NCT07140757 — Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers · recruiting
- NCT06791005 — A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. · Phase 3 · recruiting
- NCT06733740 — Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma · recruiting
- NCT06800482 — A Study of Online Follow-up in Patients With Papillary Thyroid Cancer · NA · recruiting
- NCT06133374 — Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples · recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
- NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
- NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
- NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
- NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
- NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05132205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05132205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing